Cardinal Health Grew Into Its Own Alibi

Cardinal Health's fiscal first quarter is a quiet-looking report wrapped around a loud question: what does this business grow at when you strip out the one-time item that flattered last year? The answer management gave on 2026-11-05 was $12.80 to $13.00 of EPS, up from $12.40 to $12.60 — and, pointedly, a figure described as 17%–19% growth off an ex-tariff-refund fiscal 2026 base of $10.95, rather than off the $11.26 actually reported. That is a company volunteering to be judged against the harder number.

The Refund That Vanished From the Script

It is worth sitting with how completely that theme left the building. In the prior quarter the tariff refund was the single most-emphasized concept in the entire call — referenced as a potential $200 million recovery, roughly half of which would be shared with customers, and explicitly excluded from the P&L because it was too uncertain. This quarter it survives only as a background hum inside medical products, where management noted that "modest commodity pressure, primarily in transportation costs, was offset by tariff tailwinds." No headline, no sizing, no aspirational $100 million earnings kicker. A crutch was quietly retired, and the company walked anyway.

What's underneath is the structural reality of a 4%-gross-margin distributor: at that level, small moves in the operating line are enormous. Gross margin has been flat at roughly 4% for sixteen years, yet operating margin pushed to 1.1%, up 0.4pp. Which is exactly how you get consolidated revenue up 5% to $67.5 billion but operating income up 17% to $1 billion — the first billion-dollar operating quarter in company history. Aaron Alt's line that "gross profit grew faster than SG&A" is the whole thesis in six words.

A Moat Made of Paper

The durable part of the story is contractual, not operational. Jason Hollar opened by noting the renewal of CVS Health through June 2032, and then put a number on the renewal wave: "Over the last 12 months, we have renewed contracts representing nearly two-thirds of our enterprise revenue, the majority of which is long-term in length." That included the two largest pharma customers and the two largest in medical products. It is not glamorous, but a longstanding relationship of that shape is what lets a distributor invest through a margin cycle.

The Red Oak sourcing joint venture got the most interesting exchange of the Q&A. Asked whether the benefits extend beyond 2029, Hollar was careful — "I will never speak for our customer" — but noted the relationship "certainly would transcend any spin-off on the CVS side," while Alt flagged that the loss-of-exclusivity tail is back-loaded: consistent with last year in fiscal 2027, then "a nice benefit, particularly in 2029." That is a business with a visible earnings stair-step it has not yet had to sell hard.

Urology as the Connective Tissue

The Specialty strategy is where the company sounds least like a logistics company and most like a platform. Specialty grew 18% in the quarter, with urology and oncology called out as priority areas. Hollar's answer on why urology matters is the clearest articulation of the strategy yet on a public call: “What you just described is the setup for very much the flywheel, the virtuous cycle, the ecosystem of our specialty strategy.” — Jason Hollar, Chief Executive Officer · 2026-11-05 Solaris in the MSO layer, Strive in home delivery of urology supplies, Nuclear supplying radiopharmaceuticals into those same practices, and Specialty Networks providing the group purchasing and data rails.

The tell is that the appeal is framed around the community physician — doctors who want to run a business and treat patients, and who need ancillary services to do both. Hollar was refreshingly honest about the constraint: "Our constraint is very much on our confidence that we will integrate it very successfully." Not capital, not opportunity — execution. That is the right bottleneck to have, and it also explains why the Solaris lap in Q2 will make the cadence look worse before it looks better.

The Warning Management Already Gave You

The one genuine blemish is medical products, where segment profit of $33 million came in above expectations yet guidance was nudged toward the bottom of the $200–220 million range. The cause: "sustained high petroleum costs driven by the ongoing Iran conflict." This should not be a surprise to anyone who was listening in August:

If these types of costs and rates stay elevated for the duration of our fiscal year, it's likely we'd be closer to that bottom end of our guidance range for GMPD.

That is the same warning, pre-negotiated three months early. The company has been carrying conflicts in Iran in its narrative for at least two quarters now, and it is emphatically a market theme rather than a Cardinal one — the same oil-and-freight complex shows up across the global keyword set in the energy and transport names. Against that, global medical products still beat internally on the back of Cardinal Health brand growth in the low-to-mid single digits and network simplification. A distributor that pre-announces the bad news and then beats it is a distributor with its arms around the problem.

Not so for policy. The OPPS rule finalized the night before the call pushed 340B reimbursement back into the spotlight, and Hollar's answer — health systems absorb the hit, patients shift to lower-cost sites, Cardinal picks up "our fair share" of that volume — is essentially the same posture he took in August and April, that the company's compensation should not change because its role has not. The difference now is a finalized rule rather than a proposal. He conceded the sizing question directly: "It's a little premature to predict how much."

The Tape Already Voted

None of this arrives in a vacuum. Cardinal shares are up 12.7% in the last 90 trading days and sit within 3% of their all-time high, on top of a sixteen-year run of roughly 730%. The market has spent a quarter pricing in exactly the quarter that was delivered. Meanwhile the balance sheet is doing its part: effective net cash of roughly -$2.1 billion improved 54% year over year, and interest coverage of 9.2x is a long way from where this company sat in 2023.

So what actually changed? A distributor that once needed a one-time tariff recovery to make its numbers has now guided off a base that removes it, renewed two-thirds of its revenue, and pre-announced the only segment that will disappoint. The secular trend language around Home Solutions and nuclear theranostics — revenue up 7% but profit up 16% in the "other" bucket — is doing real work now, not just narrative work. The unanswered question is whether the core distribution engine, at 1% aggregate margins, can keep compounding profit faster than revenue as the GLP-1 revenue mix dilutes and the urology integrations lap. This quarter said yes. Next quarter, with Solaris rolling off the comp, is where the answer gets tested.